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A shift toward a disease-based therapy designed according to patterns of failure and likelihood of nodal involvement predicted
by pathologic determinants has recently led to considering a selective approach to lymphadenectomy for endometrial cancer.
Therefore, it became critical to examine reproducibility of diagnosing the key determinants of risk, on preoperative endometrial
tissuesamplesaswellastheconcordancebetweenpreoperativeandpostresectionspecimens.Sixgynaecologicpathologistsassessed
105 consecutive endometrial biopsies originally reported as positive for endometrial cancer for cell type (endometrioid versus
nonendometrioid), tumor grade (FIGO 3-tiered and 2-tiered), nuclear grade, and risk category (low risk deﬁned as endometrioid
histology, grade 1 + 2 and nuclear grade <3). Interrater agreement levels were substantial for identiﬁcation of nonendometrioid
histology (κ = 0.63; SE = 0.025), high tumor grade (κ = 0.64; SE = 0.025), and risk category (κ = 0.66; SE = 0.025). The overall
agreement was fair for nuclear grade (κ = 0.21; SE = 0.025). There is agreement amongst pathologists in identifying high-
risk pathologic determinants on endometrial cancer biopsies, and these highly correlate with postresection specimens. This is
ascertainment prerequisite adaptation of the paradigm shift in surgical staging of patients with endometrial cancer.
1.Introduction
Surgery is the primary treatment modality for endometrial
cancer. In 1988, the International Federation of Gynecology
and Obstetrics (FIGO) recommended surgical staging that
includespelvicandpara-aorticlymphadenectomyinallcases
of endometrial cancer [1]. Based on the data presented
by Creasman et al. the frequency of pelvic lymph node
metastases is found in 3%, 9%, and 18% in grade 1, 2, and
3 endometrial cancer and of paraaortic involvement 2%, 5%,
and 11% in grade is 1, 2, and 3, respectively [2]. Although
surgical staging allows for accurate assessment of the extent
of disease that guides adjuvant therapy, recent data suggests
that staging may not be universally necessary. A shift toward
a disease-based therapy applied according to the likelihood
of lymph node metastases [3–5] and patterns of failure
which are predicted by pathologic determinants has recently
been introduced by Mariani et al. [6]. Accordingly, lymph
node dissection can be avoided in low-risk patients whilst
it should be considered for all non-low-risk population. In
their paper, Mariani et al. deﬁne the characteristics of low-
risk endometrial cancer as endometrioid histology, FIGO
grade 1 and 2 (low grade), less than 50% myoinvasion,
primary tumor diameter of less than 2cm, and no gross
evidence of extrauterine disease. All others may beneﬁt from
surgical staging. As lymphadenectomy in some women with
endometrial cancer may be associated with increased risk
of perioperative and postoperative morbidity and rarely
mortality [7, 8], it is desirable to identify patients who are at
signiﬁcant risk for extrauterine spread and require complete
surgical staging while sparing the majority a more morbid
procedure. Two of these four factors identiﬁed by Mariani
et al., namely, grade and cell type, are assessed and available
in preoperative specimens. Without commenting on the
clinical aspect of this dispute or on the appropriate approach
for accurate assessment of the remaining factors (tumor2 Obstetrics and Gynecology International
size and depth of myoinvasion), we identiﬁed the need
to examine the reproducibility of designating tumor grade
and cell type in cancer-positive preoperative biopsies and
their concordance with the ﬁnal pathology. Several previous
interobserver reproducibility studies assessed the diagnostic
performance of gynecologic pathologist in their assessment
of endometrial biopsies. These studies have focused on their
agreement on the spectrum of endometrial hyperplasias
bordering on FIGO grade 1 endometrioid adenocarcinoma
or the histologic dating of cycling endometrium [9–13].
This study assessed the diagnostic agreement amongst
pathologists with special expertise in gynecologic pathology,
on the two histologic features present on preoperative
endometrial biopsies harboring malignancy, namely, tumor
grade and cell type, the two features that can identify risk
stratiﬁcation for likelihood of lymph node involvement and
the concordance between preoperative diagnosis and ﬁnal
pathology.
2.MaterialsandMethods
Diagnostic agreement of a panel of six pathologists was
assessed by comparing their interpretations of endometrial
tissue samples. All six raters are academic pathologists
with a subspecialty focus in gynecologic pathology. Their
experience in gynecologic pathology ranged from 2 to 17
years. Four of the six pathologists had formal gynecologic
pathology fellowship training. One pathologist was practis-
ing in site speciﬁc sign out practise for 5 years and one par-
ticipated in the gynepathology service among other disease
sites. Each of the six pathologists assessed 105 consecutive
cancer-positive endometrial biopsies accessioned between
2001 and 2006, for cell type, tumor grade, nuclear grade,
and risk category (to be deﬁned here in after). Each rater
was masked to the original pathology report, the review of
the other ﬁve raters, and the ﬁndings in the subsequent
hysterectomy. The cell type was dichotomized to Type I
that includes endometrioid and mucinous adenocarcinomas
versus Type II (nonendometrioid) which includes serous,
clear cell, and carcinosarcomas. The analysis of agreement
on tumor grade was assessed using both FIGO 3-tiered
grading system and separately using the 2-tiered system
that merges FIGO grade 1 and 2 into low grade versus
high grade as previously described by Scholten et al. [14].
A l lT y p eI It u m o r sw e r ea s s i g n e dah i g ht u m o rg r a d e
[15]. Raters were provided with the following deﬁnitions
for nuclear grade prior to the review: nuclear grade 1
was deﬁned as oval, mildly enlarged nucleus with evenly
distributed chromatin, nuclear grade 3 was deﬁned as those
with markedly enlarged and pleomorphic nuclei, with coarse
chromatin and distinct nucleoli, and nuclear grade 2 was
characterized by intermediate features [16, 17]. Because the
purpose of this study was to examine the agreement on
identifyingcasesinwhichlymphadenectomycanbeomitted,
we also evaluated the risk category. Low risk was deﬁned as
Type I, FIGO grade 1 + 2 and nuclear grade <3. All others
were deﬁned as high risk.
Table 1: Level of agreement on tumor grade using 3-tiered system.
Diagnosis κ Strength of agreement
[15]
Atypical complex
hyperplasia 0.258 fair
FIGO grade 1 0.350 fair
FIGO grade 2 0.096 poor
FIGO grade 3 0.647 substantial
Overall 0.368 fair
2.1. Analyses of Cases Rated as Atypical Complex Hyperplasia.
Cases that were classiﬁed as atypical complex hyperplasia by
anyofthepathologistswereclassiﬁedaslowriskbasedonthe
considerable likelihood of concurrent low-grade carcinoma
observed in subsequent resection as previous reported by a
GOG study [18]. Notably, most type II endometrial cancer
arises on the background of atrophic endometrium and is
estrogen independent.
Interrater agreement levels in each category were ana-
lyzed by the Fleiss’ multiple-rater Kappa statistics with
standard error (SE). The general (conventional) consensus
scheme for strength of agreement by κ values was used in the
evaluation as follows: 0.2–0.4, fair; 0.4–0.6, moderate; 0.6–
0.8, substantial; 0.8–1, excellent [19].
The concordance between cell type and the 2-tiered
tumor grading system on the endometrial biopsy review
for each rater and the ﬁnal pathology report of the
hysterectomy was examined. The hysterectomy specimens
were not reviewed as this was beyond the scope of this
study. Intraoperative consultation by frozen section was not
performed.
Ethics approval for this study was obtained from the
Research Ethics Board of Sunnybrook Health Sciences Cen-
tre.
3. Results
All 6 pathologists completed their review addressing all
categories.
3.1. Cell Type. The overall interrater agreement level for cell
type was substantial κ = 0.63; SE = 0.025.
3.2. Tumor Grade. Table 1 summarizes the agreement
among pathologists using 3-tiered grading system. Interrater
agreement levels were substantial for identiﬁcation of high
tumor grade (κ = 0.64; SE = 0.025). The overall κ was
only fair when the 3-tiered FIGO grading system was used
(κ = 0.36, SE = 0.016) compared to substantial level of
agreement when the 2-tiered grading system was used (κ =
0.64; SE = 0.025). The diﬀerence in level of agreement
between the two grading systems (2-tiered versus 3-tiered) is
ascribedtopooragreementregardingthegrade2designation
using the 3-tiered system (κ = 0.09, SE = 0.025). Another
factor interfering with interobserver agreement was diﬀerent
threshold for grade 1 endometrioid adenocarcinoma. In 14Obstetrics and Gynecology International 3
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Figure 1: Percentage of cases by degree of agreement in each
category.
cases, 1 to 4 of the 6 raters classiﬁed the lesion as complex
hyperplasia with atypia. Therefore, the agreement on grade 1
and complex hyperplasia with atypia was only fair (κ = 0.35;
SE = 0.025 and κ = 0.25; SE = 0.025, resp.).
3.3. Nuclear Grade. The overall agreement was fair for
nucleargrade(κ = 0.21;SE = 0.025)althoughtheagreement
on identiﬁcation of nuclear grade 3 was moderate (κ =
0.52; SE = 0.016), better than the overall agreement in this
category.
3.4. Risk Category. When cases were classiﬁed into two risk
categorieswithhighriskdeﬁnedbythepresenceofanyofthe
following features: nonendometrioid cell type, high tumor
grade, or high nuclear grade, the interrater agreement level
was substantial (κ = 0.66; SE = 0.025). Figure 1 illustrates
the proportion of cases by the degree of agreement in each
category.
3.5. Correlation with Resection Specimens. In 85/105 cases,
theprimarysurgicaltreatmentwascarriedoutinourinstitu-
tion.Weexaminedtheconcordancebetweentheendometrial
biopsy and the ﬁnal pathology report in the subsequent
hysterectomyspecimenoncelltypeand2-tieredtumorgrade
for each individual pathologist. On average in 89.2±4.7% of
the cases, there was agreement amongst the raters between
the cell type determined on the endometrial biopsy with
the cell type reported on the resection specimen. Agreement
between tumor grade (2-tiered system) determined on the
endometrial biopsy and the grade reported in the resection
s p e c i m e n so c c u r r e do na v e r a g ei n8 4 .3 ± 5.9% of cases.
Table 2 details the concordance and incidence of under-
calling per rater. Overall there were 24 cases with non
endometrioid or grade 3 endometrioid adenocarcinoma on
ﬁnal resection. Of those the raters identiﬁed 14–18 of them
as either nonendometrioid or grade 3.
4. Discussion
We examined the level of agreement on the interpretation
of preoperative endometrial biopsies regarding cell type,
2-tiered and 3-tiered grading system, nuclear grade, and
risk for lymph node involvement categories. To the best of
our knowledge, this is the ﬁrst report on the interobserver
reproducibility between multiple pathologists regarding
tumor characteristics identiﬁed on preoperative endometrial
biopsies that are important in selecting patients for complete
surgical staging. Interrater agreement levels were substantial
for identiﬁcation of nonendometrioid histology, high tumor
grade, and risk category, a combination of factors which
determine the need for surgical staging.
In western countries endometrial carcinoma is the most
common malignancy of the female genital tract. The extent
of surgery, in particular lymphadenectomy, has been the
focus of protracted debate in the last two decades [20–
29]. Despite FIGO’s recommendation for lymphadenectomy,
the frequency of lymph node staging varies in diﬀerent
countries and even between diﬀerent centers. In North
America outside the setting of clinical trials and tertiary care
centers not all patients with EEA are formally staged [20, 30–
35]. Moreover, statistics in both Canada and the United
States conﬁrm that, even in countries with a wellrecognized,
board-certiﬁed subspecialty in gynecologic oncology, only a
minorityofpatientsareeverseenbyagynecologiconcologist
[36–38]. Previous data has shown that there is a substantial
proportion of patients, with a low risk of nodal metastasis
and nodal failure following simple surgery who would not
beneﬁt from lymphadenectomy and hence can be managed
bysimplehysterectomyandbilateralsalpingo-oophorectomy
by general gynecologists in community hospitals while
pelvic and paraortic lymphadenectomy should be limited
to patients with a signiﬁcant risk for nodal involvement or
nodal failure [39, 40]. In our tertiary care centre, about
55% of all endometrioid endometrial cancer patients are
low grade and FIGO stage IA or IB [41]. Based on the
Surveillance, Epidemiology, and End Results (SEERs) data
summarizing almost 40,000 endometrioid corpus cancers,
63% of cases are stage IA or IB and 83% are low grade
[42]. The deﬁnition of this high-risk subset varies among
studies; however, all include non-endometriod histology and
high FIGO grade as important features to identify those
who should be surgically staged. These tumor attributes
are present in the preoperative specimen and available to
the clinician prior to deﬁnitive surgery. In a recent review
of the literature, Leitao identiﬁed that the rate of nodal
metastasis reported in previous studies was based on tumor
grade and cell type in the ﬁnal pathology of the resection
specimen and not in preoperative biopsy assessment [43].
Given that this information is present preoperatively and
can help the clinician decide on the need to undertake
lymph node dissection if accurate, it became desirable to
examine interobserver agreement on cell type and grade on
preoperative specimens as well as their concordance with the
ﬁnal characteristics determined on resection specimens.
When 3-tiered tumor grading system was used, the over-
a l la g r e e m e n tw a sf a i r( Table 1). This is attributed to both4 Obstetrics and Gynecology International
Table 2: Concordance between interpretation of endometrial biopsies by rater and paired resection specimens (available in 85 patients).
Cell Type 2-Tiered Tumor Grade
Concordant Discordant Under-called Concordant Discordant Under-called
Rater N % N % N % N % N % N %
No. 1 79 92.9 6 7.06 1 1.18 76 89.4 9 10.59 7 8.22
No. 2 74 87.1 10 11.8 5 5.88 72 84.7 13 15.29 8 9.41
No. 3 71 83.5 14 16.5 2 2.35 69 81.2 16 18.82 5 5.88
No. 4 72 84.7 13 15.3 5 5.88 64 75.3 21 24.71 9 10.59
No. 5 79 92.9 6 7.06 2 2.35 71 83.5 14 16.47 7 8.234
No. 6 80 94.1 5 5.88 4 4.71 78 91.8 7 8.235 6 7.06
poor agreement on FIGO grade 2 and on interpreting cases
bordering on atypical complex hyperplasia. The distinction
between grade 1 and 2 carcinoma is challenging given that
it is based on quantitative estimation of nonsquamous solid
a r e a sw i t hac u t o ﬀ value of 5%. For most pathologists, it
is extremely diﬃcult to accurately distinguish between 5%
and 6% and even 10%. Moreover, when keratinization is
not obvious, some squamous areas may be included in the
percentage of solid areas. Our observation regarding poor
agreement regarding the designation of FIGO grade 2 is
in line with a previous report by Taylor et al. Using a
two-tiered system for assessing uterine tumor grade with a
delineating value of the presence of 20% nonsquamous solid
tumor, the authors found less interobserver variation (κ =
0.966) compared to the current three-tiered grading system
(κ = 0.526) [44]. Similarly, Lax et al. [45]r e p o r t e ds u p e r i o r
agreement on the 2-tiered compared with FIGO 3-tiered
grading systems. These authors tested the agreement on
resection specimens and deﬁned high grade as the presence
of at least two of the following three criteria: (1) more
than 50% solid growth (without distinction of squamous
from nonsquamous epithelium); (2) a diﬀusely inﬁltrative,
rather than expansive, growth pattern; and (3) tumor cell
necrosis. The overall fair κ for tumor grade using 3-tiered
system (Table 1) also reﬂects the known disagreement on
casesthat bordered onatypical complex hyperplasia[46,47].
Comparison between an artiﬁcial 2-tiered FIGO grading
and Lax’s binary grading system demonstrated that a simple
architectural binary grading system that divided tumors
into low-grade lesions and high-grade lesions based on the
proportion of solid growth (equal or less than 50% or
greaterthan50%)hadsuperiorprognosticpowerandgreater
reproducibility [48].
Various reasons for poor reproducibility have been
proposed including variablyapplied criteriaforthediagnosis
of atypia and complicating features such as metaplasia or
polyps. The distinction between atypical complex hyper-
plasia and FIGO grade 1 endometrioid adenocarcinoma is
irrelevant for our discussion as both should be regarded as
non-high-risk patients in whom lymphadenectomy could be
omitted. As reported earlier by others [49], the overall agree-
ment in our study was fair for nuclear grade although the
agreement on identiﬁcation of nuclear grade 3 was moderate
when predeﬁned criteria were provided. In accordance with
our observation, poor reproducibility of nuclear grade was
documented previously on hysterectomy specimens [50].
It has been argued previously that identiﬁcation of low-
risk patients has been based on the grade assigned on
resection and not on biopsy material, and that tumor grade
appreciatedonbiopsiespoorlycorrelateswiththeﬁnalresec-
tion specimen [51]. We have shown that preoperative grade
and cell type can be identiﬁed accurately preoperatively and
may be used to assess the risk of lymph node metastases.
The likelihood of undercalling that could potentially result
in understaging was low. Under-calling occurred in 6–16%
of the cases regarding the cell type and in 6–11% of cases
regarding tumor grade (Table 1). Seventy percent of the
cases undercalled as endometrioid histology on biopsies but
proved to be nonendometrioid on hysterectomy specimen
had been designated as high-grade endometrioid disease and
therefore would not have resulted in undertreatment because
they would still be designated to be in the high-risk category
requiring staging. Previously reported concordance rates on
grade between preoperative and hysterectomy specimens
werelowercomparedwithourobservation.Thesestudiesare
based on 3-tiered grading system. The overall concordance
reported earlier was 64.5%, and the concordance for grade
3 tumors was signiﬁcantly higher than that for grade 1
[52]. Another study found that the concordance rates were
20% in grade 1, 61.5% in grade 2, and 77.8% in grade
3[ 53]. Eltabbakh et al. found that of those women with
grade 1 endometrial carcinoma diagnosed preoperatively,
23% and 6% had grade 2 and 3 disease, respectively, in the
hysterectomy specimen [54]. This supports our observation
that over 85% of the time high tumor grade determined on
biopsy concurred with those of the hysterectomy specimens.
Although all six pathologists involved in this study had
a subspecialty focus in gynecologic pathology, they had
reasonable diverse background since half of them joined
the group less than 6 months prior to the onset of this
review. The demonstrated substantial agreement among
gynecologic pathologists in identifying cases that require
surgical staging needs to be further investigated in the
nonacademic setting and among surgical pathologists with
no particular gynecologic pathology fellowship training or
exceptional expertise.
In conclusion, there is considerable agreement among
gynecologic pathologists in identifying high-risk pathologicObstetrics and Gynecology International 5
determinants on the preoperative endometrial cancer biop-
sies which also correlates with the ﬁnal pathology. This
ascertainment is critical to substantiate the paradigm shift in
surgical staging of patients with endometrial cancer.
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